Immune recovery after cyclophosphamide treatment in multiple myeloma: implication for maintenance immunotherapy.

Bone Marrow Research Pub Date : 2011-01-01 Epub Date: 2011-04-06 DOI:10.1155/2011/269519
Amir Sharabi, Nechama Haran-Ghera
{"title":"Immune recovery after cyclophosphamide treatment in multiple myeloma: implication for maintenance immunotherapy.","authors":"Amir Sharabi,&nbsp;Nechama Haran-Ghera","doi":"10.1155/2011/269519","DOIUrl":null,"url":null,"abstract":"<p><p>Multiple myeloma (MM) is a progressive B-lineage neoplasia characterized by clonal proliferation of malignant plasma cells. Increased numbers of regulatory T cells (Tregs) were determined in mouse models and in patients with MM, which correlated with disease burden. Thus, it became rational to target Tregs for treating MM. The effects of common chemotherapeutic drugs on Tregs are reviewed with a focus on cyclophosphamide (CYC). Studies indicated that selective depletion of Tregs may be accomplished following the administration of a low-dose CYC. We report that continuous nonfrequent administrations of CYC at low doses block the renewal of Tregs in MM-affected mice and enable the restoration of an efficient immune response against the tumor cells, thereby leading to prolonged survival and prevention of disease recurrence. Hence, distinctive time-schedule injections of low-dose CYC are beneficial for breaking immune tolerance against MM tumor cells.</p>","PeriodicalId":9220,"journal":{"name":"Bone Marrow Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2011/269519","citationCount":"20","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bone Marrow Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2011/269519","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2011/4/6 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 20

Abstract

Multiple myeloma (MM) is a progressive B-lineage neoplasia characterized by clonal proliferation of malignant plasma cells. Increased numbers of regulatory T cells (Tregs) were determined in mouse models and in patients with MM, which correlated with disease burden. Thus, it became rational to target Tregs for treating MM. The effects of common chemotherapeutic drugs on Tregs are reviewed with a focus on cyclophosphamide (CYC). Studies indicated that selective depletion of Tregs may be accomplished following the administration of a low-dose CYC. We report that continuous nonfrequent administrations of CYC at low doses block the renewal of Tregs in MM-affected mice and enable the restoration of an efficient immune response against the tumor cells, thereby leading to prolonged survival and prevention of disease recurrence. Hence, distinctive time-schedule injections of low-dose CYC are beneficial for breaking immune tolerance against MM tumor cells.

Abstract Image

多发性骨髓瘤环磷酰胺治疗后的免疫恢复:对维持免疫治疗的意义。
多发性骨髓瘤(MM)是一种以恶性浆细胞克隆增生为特征的进行性b系肿瘤。在小鼠模型和MM患者中检测到调节性T细胞(Tregs)数量增加,这与疾病负担相关。因此,将Tregs作为治疗MM的靶点是合理的。本文综述了常用化疗药物对Tregs的作用,重点介绍了环磷酰胺(CYC)。研究表明,Tregs的选择性消耗可以在给予低剂量CYC后完成。我们报道,持续不频繁的低剂量CYC可阻断mm影响小鼠Tregs的更新,使其能够恢复针对肿瘤细胞的有效免疫反应,从而延长存活时间并预防疾病复发。因此,独特的时间安排注射低剂量CYC有利于打破对MM肿瘤细胞的免疫耐受。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信